Intended for healthcare professionals


Update to living WHO guideline on drugs for covid-19

BMJ 2023; 380 doi: (Published 12 January 2023) Cite this as: BMJ 2023;380:p57

This living guideline by Lamontagne and colleagues (BMJ 2020;370:m3379) has been updated. For the latest update, visit doi:10.1136/bmj.m3379. The latest version of this WHO living guidance does not include any changes to the strength or direction of recommendations, but rather has new data to support existing recommendations:

  1. The use of nirmatrelvir/ritonavir is now considered to be an option also for pregnant and breastfeeding women with non-severe covid-19

  2. Evidence of reduction of in vitro neutralisation activity supports the strong recommendations against the use of the neutralising monoclonal antibodies sotrovimab and casirivimab-imdevimab